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Abstract
Background Non-human primate (NHP) diabetic models using chemical
ablation of b-cells with STZ have been achieved by several research groups.
Chemotherapeutic STZ could lead to serious adverse events including neph-
rotoxicity, hepatotoxicity, and mortality.
Methods We implemented a comprehensive therapeutic strategy that
included the tether system, permanent indwelling catheter implants, an
aggressive hydration protocol, management for pain with IV nubain and
anxiety with IV midazolam, moment-by-moment monitoring of glucose lev-
els post-STZ administration, and continuous intravenous insulin therapy.
Results A triphasic response in blood glucose after STZ administration was
fully characterized. A dangerous hypoglycemic phase was also detected in all
baboons. Other significant findings were hyperglycemia associated with low
levels of plasma leptin, insulin and C-peptide concentrations, hyperglucagon-
emia, and elevated non-esterified fatty acids (NEFA) concentrations.
Conclusions We successfully induced frank diabetes by IV administering a
single dose of pharmaceutical-grade STZ safely and without adverse events
in conscious tethered baboons.
Introduction
Both major forms of diabetes mellitus (DM) involve
beta cell (b-cell) destruction and dysfunction. Type 1
DM (T1DM) involves severe insulin deficiency caused
by autoimmune destruction of islet b-cells. In long-
standing T1DM, up to 99% of islet mass is lost [45].
Type 2 diabetes (T2DM) develops when insulin secre-
tory capacity no longer compensates for peripheral insu-
lin resistance. In long-standing T2DM, approximately
65% of islet mass is destroyed by apoptosis, which
appears to be mediated primarily by lipotoxicity and/or
glucotoxicity [4]. Accordingly, new treatment strategies
have focused on replenishing the deficiency of b-cell
mass common to both major forms of diabetes by islet
transplantation or b-cell regeneration [8].
Islet transplantation has been investigated as a treat-
ment for T1DM in selected patients with inadequate
glucose control despite insulin therapy. Although the
outcome of the procedure has improved dramatically
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over the past decade, it remains an invasive procedure
with a substantial risk of morbidity [51, 62]. A major
cause for the high incidence of failure in human clinical
allotransplantations is the poor availability of trans-
planted pancreatic tissue. To improve the clinical out-
come of human islet allotransplantation, the realization
of well-designed preclinical studies in animal models
remains crucial.
Animal models for T1DM range from animals with
spontaneously developing autoimmune diabetes to
chemical ablation of the pancreatic b-cells. Some of the
most commonly used models of T1DM are chemically
induced, spontaneous autoimmune, genetically induced
and virally induced models [36]. Islet regeneration has
been successful in animal models, primarily targeting
liver using viral vectors [19, 37]. As islet mass is known
to increase during obesity and pregnancy, the concept of
stimulating pancreatic islet regeneration in vivo is both
rational and physiologic [34, 66].
Rodent models of T1DM have been extensively stud-
ied. However, these rodent homologues are limited as
translational models by their small size and brief life
span and that biological outcomes in rodents may not
faithfully reflect the clinical manifestations of such find-
ings in humans. Many of these limitations can be over-
come by identifying large animals with genetic diseases,
such as diabetes, corresponding to their human disease
counterparts [9]. Over the years, non-human primates
(NHP) have been used in studies regarding important
historical and current diseases such as human immuno-
deficiency virus, tuberculosis, hepatitis, polio, and
malaria [5]. Advantages of using NHP are their size and
long lifespan compared to mice and rats. Their larger
size permits a wider range of procedures to be per-
formed, and the animals live long enough to be able to
monitor and track long-term effects of conditions and
treatments [26].
Baboons are ideal NHP models for studying the bio-
logical and genetic aspects of human disease. There is a
considerable resemblance when comparing baboon
anatomy and physiology to that of humans. The biolog-
ical processes related to growth, development, matura-
tion, reproduction, senescence, the reproductive system,
bone structure, dental growth, cardiac function, and
metabolic disturbances in baboons are significantly simi-
lar to humans [15]. The major histocompatibility com-
plex (MHC) bears a striking resemblance to humans.
The similarity of the MHC between NHP and humans
compared to that between rodents and humans has
allowed for critical development in standard medical
practices including vaccination protocol development,
blood transfusion protocol development, and organ
compatibility and transplantation [15].
Nevertheless, in large animal models such as the
baboon, spontaneous diabetes is relatively rare; there-
fore, induced NHP models of T1DM are required. Dif-
ferent strategies have been used to induce hyperglycemia
in baboons, mainly by pancreatectomy or streptozotocin
(STZ). Pancreatectomy has been used to induce diabetes
in pigs [47], dogs [20], and primates [27]. This method
requires invasive intra-abdominal surgery in which the
exocrine pancreas function is removed, leading to pan-
creatic exocrine deficiency in the animal and the need
for enzyme supplementation [17]. This approach also
requires a skilled surgeon because the tight adherence
of the pancreas to the intestines makes pancreatectomy
in baboons a complicated intervention [70].
Multiple NHP diabetic models using chemical abla-
tion of b-cells with STZ have been achieved by several
research groups [67]. STZ is widely used to induce
experimental diabetes in animals. The mechanism of its
action in b-cells of the pancreas has been intensively
investigated. The cytotoxic action of this diabetogenic
agent is mediated by reactive oxygen species. STZ enters
the b-cell via a glucose transporter (GLUT2) and causes
alkylation of DNA. DNA damage induces activation of
poly ADP-ribosylation, a process that is more impor-
tant for the diabetogenicity of STZ than DNA damage
itself. Poly ADP-ribosylation leads to depletion of cellu-
lar NAD+ and ATP. Enhanced ATP dephosphorylation
after STZ treatment supplies a substrate for xanthine
oxidase resulting in the formation of superoxide radi-
cals. Consequently, hydrogen peroxide and hydroxyl
radicals are also generated. Furthermore, STZ liberates
toxic amounts of nitric oxide that inhibit aconitase
activity and participates in DNA damage. As a result of
the STZ action, b-cells undergo the destruction by
necrosis [41].
Clinically relevant adverse effects have been reported
with the administration of STZ in healthy juvenile and
adult NHP [22]. As STZ is an alkylating cytotoxic agent,
it could lead to serious adverse events including nephro-
toxicity, hepatotoxicity, and mortality resulting from
organ failure or severe metabolic perturbations [55].
Except for a recent report [21], there are no sufficient
data concerning the appropriate management and treat-
ment of adverse effects for STZ use in NHP in the litera-
ture [39].
Here, we report our findings with the use of pharma-
ceutical-grade STZ with the intention of instituting a
safer strategy to induce hyperglycemia in conscious teth-
ered baboons. Therefore, the primary aim of this docu-
ment was the establishment of a model of induced frank
diabetes in baboons through b-cell compromise with
STZ under a tether system and indwelling catheter
implants.
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Materials and methods
Humane care guidelines
Animals were strictly handled in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals by the National Institutes of
Health, the Animal Welfare Act by the United States
Department of Agriculture, and the Weatherall report
by the Medical Research Council. The protocol was
approved by the Institutional Animal Care and Use
Committees of the Texas Biomedical Research Institute
and Baylor Research Institute (Assurance Number: 10–
4233). The study approval ID was IACUC 1251PC.
Animal selection and acclimation
Four healthy adult male baboons (ID Nos. 18175,
26104, 20105, 26457), age >6 but <16 y.o., weighing 26–
34 kg were selected to go into the study. The baboons
studied are selected from a population at the Southwest
National Primate Research Center (SNPRC) located at
the Texas Biomedical Research Institute (Texas Bio-
med) San Antonio, TX [13, 15]. These animals develop
spontaneous and diet-induced obesity and its comorbid-
ities [13]. The DNA sequence of genes such as leptin and
adiponectin shows a 95–99% correspondence of
sequence identity at the DNA, RNA, and predicted pro-
tein level with humans [63]. Our laboratory has also
documented impaired insulin signaling at the whole
body and molecular level and overt diabetes in sponta-
neously obese baboons [3, 10].
Animals were not included in the study if they had
lost more than 3 kg of weight in the last 3 months.
However, animals were included if they had not been
weighed recently, but they had good health according to
veterinarian’s clinical decision. They were monitored
regarding their food consumption as well their behav-
ioral traits during the acclimation period. Animal accli-
mation to technician presence was carefully undertaken
prior to the procedure start date. Most of these criteria
were subjective and assessed by individuals working clo-
sely with the animals. As such, the study veterinarian in
conjunction with the lead technical staff was best quali-
fied to make recommendations regarding behavior. An
additional animal remained on sham-tether, accompa-
nying the selected baboon in the bay. The accompany-
ing animal was kept on sham-tether through the
successful catheter implant of the study animal. In the
event something went wrong, a second animal was
immediately available to stay on schedule. Once the
implanted catheters into the study animal were success-
ful, the sham-tether from the accompanying animal was
removed. Eligibility and exclusion criteria followed rec-
ommendations previously described to evaluate clinical
suitability for STZ administration [21].
The quantity of food offered to each baboon daily
was based on the estimated metabolizable energy (ME)
requirements for adult captive baboons. Specifically, the
animals were fed with standard chow (monkey diet
15%, Constant Nutrition Purina 5LE0TM) to sustain
constant body weight (BW): 48 kcal 9 BW (kg) [48].
The 5LE0 food ration was weighed before distribution.
All bagged pellets were delivered to the technicians. At
the end of the day, any part of the ration remaining in
the food hopper was estimated as a percentage accord-
ing to the best of the veterinary technician’s knowledge.
Their diet was enriched with fresh fruits, vegetables,
grains, and nuts. They were offered water ad libitum.
Standard chow (5LE0) was offered in daily rations
divided in two equal quantities.
The tether system and indwelling catheter implants
All animals in the study underwent surgical tether
implantation. Catheter implants in the femoral artery
and vein for tether were prepared as follows: heparin
(low-molecular weight)-coated polyurethane catheters
(Solomon Scientific, Plymouth, PA, USA) were placed
in the femoral artery and vein. An incision was made
over the femoral artery and vein just below the inguinal
lymph node, and the femoral artery/vein was exposed
by blunt dissection. Through a small incision in the ves-
sel (artery/vein), a catheter was introduced. The catheter
was advanced, secured, and tested for flow. A tension
loop was formed and secured under the skin. Both cath-
eters were routed subcutaneously to the midscapular
region of the back where they exited the skin into a
molded plastic box (backpack) attached to the tether
jacket [12].
Intensive hydration protocol, management for
discomfort and anxiety, and analgesia for pain relief
After fasting overnight, all baboons were pre-hydrated
with saline solution (NaCl) 0.9% intravenous (IV) at a
rate of 30 ml/kg of body weight/day for 24 hours before
STZ administration to decrease the likelihood of kidney
toxicity [52]. The rate of fluid administration remained
the same for 48 hours more after STZ administration.
However, fluid administration rate and/or dextrose 5%
or higher was adjusted and/or exchanged with the saline
solution, according to each animal’s clinical needs as
dictated by blood glucose and insulin therapy efficacy.
We administered the synthetic opioid agonist–antago-
nist analgesic nalbuphine hydrochloride (Nubain) (Endo
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Pharmaceuticals Inc., Chadds Ford, PA, USA) at a dos-
age of 0.15 mg 9 kg IV every 6 hours starting 24 hours
before the STZ administration, remaining with the same
regime for 48 hours after STZ administration. We also
administered midazolam (LGM Pharma, Nashville, TN,
USA). This is a short-acting drug in the benzodiazepine
class. Midazolam has a fast recovery time and is the
most commonly used benzodiazepine as a pre-medica-
tion for sedation. It is the most popular benzodiazepine
in the intensive care unit (ICU) because of its short elim-
ination half-life, combined with its water solubility and
its suitability for continuous infusion [7]. We adminis-
tered midazolam IV at an initial priming dose of 0.025–
0.05 mg/kg using the tether catheter system prior to
STZ administration. A continuous IV infusion of mi-
dazolam was administered after the priming dose for
24 hours with a dosage range of 0.02 mg/kg/hour to
0.1 mg/kg/hour. This dosage was expected to provide
an anxiolytic effect, not a sedative effect. We adminis-
tered both drugs for comfort and a means of relieving
organic stress and pain due to the sudden exposure to
the cytotoxic drug.
Induction of the diabetic phenotype with
pharmaceutical-grade streptozotocin dose
administration
A single IV injection of pharmaceutical-grade STZ
(Zanosar) at a flat-fixed dosing of 150 mg/kg was
administered. STZ (Zanosar) is indicated in the treat-
ment of metastatic islet cell carcinoma of the pancreas
in humans. Renal toxicity is dose-related and cumula-
tive. Other side effects are nausea and vomiting. In addi-
tion, liver dysfunction, diarrhea, and hematological
changes have been observed in some human patients.
Each vial of pharmaceutical-grade STZ (Zanosar; Sicor
Pharmaceuticals, Irvine, CA, USA) contains 1 g of the
active ingredient streptozotocin, and 220 mg citric acid
anhydrous. STZ (Zanosar) is available as a sterile, pale
yellow, freeze-dried preparation for intravenous admin-
istration. The pH has been adjusted with sodium
hydroxide.
To prepare STZ, Zanosar was reconstituted with
9.5 ml of cold 0.9% NaCl for IV administration. To
avoid decomposition after reconstitution, immediately
after preparation STZ was administered as an IV bolus.
When reconstituted as directed, the pH of the solution is
between 3.5 and 4.5. STZ (Zanosar) is very soluble in
water or physiological saline and must be protected
from light. Caution in the handling and preparation of
the powder and solution should be exercised, and the
use of gloves is recommended. If the sterile powder or a
solution prepared from STZ (Zanosar) contacts the skin
or mucosa, the affected area must be immediately
washed with soap and water [6, 29].
Close monitoring of glucose levels post-STZ
administration
The most dangerous and significant adverse effect
immediately after STZ administration is severe hypogly-
cemia [42]. Therefore, repeated measurements of glucose
levels are mandatory. Blood samples were drawn as fre-
quently as needed within the first 24 hours, taking
advantage of the indwelling arterial catheter. However,
15-minute draws were the standard interval during such
24 hours for an ideal clinical follow-up. 0.1 ml of arte-
rial blood was drawn to measure glucose on-site with a
conventional glucometer. The blood draw interval dur-
ing the following 48 hours was every 30–60 minutes,
but such intervals were dictated by the measured circu-
lating glucose levels.
Dextrose 50% (1 ml 9 kg IV bolus) was adminis-
tered if blood glucose levels showed a curve of glu-
cose decreasing to levels below 75 mg/dl at any time
point after the STZ administration. At the same time,
a bag with 10–30% dextrose in 1000 ml of saline was
continuously administered at a rate of approximately
30–40 ml/hour during the first 48–72 hours. The
length of administration for this 10–30% dextrose
bag was dictated by the levels of glucose in the fol-
lowing hours post-STZ administration. We eventually
withdrew the continuous glucose administration and
exchanged it for saline NaCl 0.9% when frank hyper-
glycemia was confirmed. Depending upon glucose val-
ues, continuous IV insulin was initiated (Fig. 3). The
glucose infusion rate (GIR) was calculated according
to the established formula:
Continuous intravenous insulin therapy
We administered a continuous IV insulin infusion
(Humulin-R U-100, human, USP, rDNA; Elli Lily Co.,
Indianapolis, IN, USA) using a Baxter infusion pump
(Model AS50; Baxter Health Care Corporation, Deer-
field, IL, USA), utilizing a dosage of 0.1–0.5 U/kg/hour.
The dosage was adjusted according to the response of
GIR ¼ IV Rate (ml/hour)Dextrose Conc (g/dl) 1000 (mg/g)
Weight (kg) 60 (minute/hour) (ml/dl)
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the animal and to the glucose levels both in fed and fast-
ing conditions. The goal was to maintain daily circulat-
ing glucose levels between 100 and 200 mg/dl. The
directions for insulin syringe preparation are as follows:
draw 19 ml of 0.9% non-heparinized sodium chloride
into a 20-cc BD syringe. Add 1 ml of whole blood and
20 units insulin (Humulin-R) (0.2 cc) to the syringe.
Invert the syringe to mix. Place the syringe on the Baxter
pump to begin infusing immediately. Set pump speed to
ml/hour equivalent of U/kg/hour. It is important to fol-
low the order when mixing the insulin syringes: saline
first, then blood, and finally insulin. The reason is that
the blood prevents the insulin from binding with the
plastic of the syringe, so it is critical that the blood be
added to the saline prior to the insulin in the syringe.
Analysis of metabolites and hormones to confirm the
induction of the diabetic state
After 36–42 hours, the glucose infusion was stopped,
and diabetes was confirmed by the persistence of fasting
hyperglycemia. One week before and 1 week following
STZ administration, an intravenous glucose tolerance
test (IVGTT) was performed, with glucose, insulin,
C-peptide, and glucagon concentrations measured for
60 minutes. Midazolam was administered as an anxio-
lytic agent during the one-hour conscious IVGTT as
described above. A bolus of 50% dextrose (0.5 mg/kg)
was given IV over 60 s. Arterial blood samples were col-
lected at 2, 4, 6, 8, 10, 15, 30, 45, and 60 minutes post-
dextrose administration. The midazolam was stopped
promptly upon collection of the final blood sample.
A fasting plasma glucose level of >200 mg/dl in com-
bination with C-peptide levels of less than 0.4 ng/ml,
accompanied with the absence of a stimulated C-peptide
response upon an IVGTT (0.3 ng/ml), was considered
to be indicative of diabetes in accordance with estab-
lished criteria [14]. All animals became diabetic between
36 and 42 hours after STZ administration. An excess of
circulating levels of glucagon (hyperglucagonemia) was
significantly present after STZ administration, both fast-
ing and during the IVGTT. Decreased levels of leptin
and increased levels of non-esterified fatty acids (NEFA)
were also found after STZ administration.
Serum concentrations of glucose were determined
using an ACE chemistry analyzer (Alfa Wasserman
Diagnostic Technologies, LLC, West Caldwell, NJ,
USA). Serum insulin, glucagon, leptin, and C-peptide
were determined using a DPC Immulite 1000 Analyzer
(Diagnostics Products Corporation, Los Angeles, CA,
USA). The Immulite is an automated chemiluminescent
peptide and steroid hormone analyzer. For measure-
ments of plasma free fatty acid (FFA) concentrations,
enzymatic kits were used (WAKO, Richmond, VA,
USA).
Total parenteral nutrition
Total parenteral nutrition (TPN) is generally indicated
as an anticipation of undernutrition. We established a
clinical criteria to consider immediate IV administration
of TPN if any of our STZ-treated baboons would eat
20% or less (~100 mg or less) of normal chow 5LE0 in a
48-hour period. The critical period was 72 hours after
STZ IV injection. We designed and manufactured our
routine TPN treatment to be able to provide fluids (sal-
ine 0.9% 30 ml/kg/day), energy calories (30–60 Kcal/
kg/day, depending on energy expenditure), carbohy-
drates calculated as 60% from the total amount of
Kcal/kg/day (50% dextrose providing 0.5 gr/ml), amino
acids 1.0–2.0 g/kg/day, depending on the degree of
catabolism (trophamine 500 ml, 10% specialty amino
acids injection), fatty acids calculated as 40% of essen-
tial fatty acids administered from the total amount of
Kcal/kg/day (intralipid 20% IV fat emulsion in 500 ml),
40 ml of calcium gluconate (calcium gluconate injection,
USP, 10%, 23.25 mEq/50 ml), 10 ml of potassium chlo-
ride (2 meq/ml), 2 ml of trace elements (zinc, copper,
manganese, chromium, selenium as multitrace five con-
centrate USP), 5 ml of multivitamin for infusion (M.V.I
Pediatric), and 20 mg of famotidine injection. Calcium
gluconate, potassium chloride, the trace elements, the
M.V.I, and famotidine were administered in a 24-hour
period as a mixture to the bag of TPN. This treatment
represents the standard of care in humans.
Euthanasia and histopathology examination
When euthanasia was scheduled, the animal was sedated
with ketamine hydrochloride (10 mg/kg). Then, an
overdose of sodium pentobarbital (>100 mg/kg) was
administered IV to effect. This is the preferred form of
euthanasia in non-human primates. The procedure was
performed by a veterinarian assisted by a senior veteri-
nary technician. This procedure was in accord with
guidelines established by the Panel on Euthanasia of the
American Veterinary Medical Association. After eutha-
nasia, samples of pancreas were collected, refrigerated/
frozen, and fixed for additional analyses, including his-
topathology and immunohistochemistry.
Samples of the tissues were cut into pieces, fixed in
10% buffered formalin and 4% paraformaldehyde, and
stained with hematoxylin and eosin. Pancreatic cryostat
sections 7–10 lm in thickness were fixed in 4% parafor-
maldehyde for 15 minutes at 4°C and quenched for
5 minutes with 10 mM glycine in phosphate-buffered
J Med Primatol 44 (2015) 202–217
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd206
STZ-induced diabetes in tethered baboons Frost et al.
saline (PBS). Sections were then rinsed in PBS three
times and permeabilized with 0.5% Triton X-100 in PBS
for 10 minutes. Sections were blocked with 10% vol/vol
goat serum at 37°C for 1 hour and washed three times
with PBS. Primary antibodies (anti-insulin, antigluca-
gon) were added and incubated at 4°C overnight. After
washing with PBS three times for 5 minutes each time,
secondary antibody was added and incubated for 1 hour
at 37°C. Sections were rinsed three times with PBS for
5 minutes each time, DAPI (1:5000 dilutions with PBS)
for 5 minutes, washed two times with PBS, and then
mounted.
Early detection of adverse effects
At the time of catheter placement, blood was collected
to complete a comprehensive laboratory workup and
establish baseline values for complete blood count
(CBC) with differential, routine chemistry panel, and
HbA1C. The blood chemistries and metabolic factors
measured are albumin, alkaline phosphatase, ALT,
AST, BUN, serum chloride, creatinine, potassium,
serum sodium, total protein, HbA1c, glucose, insulin,
C-peptide, NEFA, leptin, and glucagon. The complete
laboratory workup was repeated after STZ administra-
tion for early detection, assessment, and close monitor-
ing of adverse effects to kidney and liver.
Data analysis
Data analysis was performed with STATVIEW software
(SAS, Cary, NC, USA). The results are expressed as the
mean  one standard deviation. Differences were ana-
lyzed by repeated-measures ANOVA with Fisher’s post
hoc test and considered significant at P < 0.05.
Results
Circulating values of fasting insulin–glucose axis
phenotypes before and after the administration of
pharmaceutical-grade (STZ)
Pre-STZ blood glucose concentrations reported a mean
value of 83.2  10.3 mg/dl, exhibiting mean elevated
post-STZ glucose levels of 247.25  66.5 mg/dl; all
these biochemical changes occurred within 8 days after
(A) (B) (C)
(D) (E) (F)
Fig. 1 Values of key hormones and metabo-
lites influencing the physiologic control of
the insulin–glucose axis and the alpha and
beta cell biology. (A) Fasting plasma glucose
concentrations before and after STZ. (B)
Fasting plasma insulin concentrations before
and after STZ. (C) Fasting plasma C-peptide
concentrations before and after STZ. (D)
Fasting plasma glucagon concentrations
before and after STZ. (E) Fasting plasma
insulin concentrations before and after STZ.
(F) Fasting plasma NEFA concentrations
before and after STZ. Throughout the figure,
the data are shown as the mean  SD
descriptive type.
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STZ administration (Fig. 1A). Mean insulin levels
decreased from 9.3  3.4 lU/ml before STZ injection
to 2.3  0.5 lU/ml after STZ injection (Fig. 1B). Mean
C-peptide levels decreased from 0.545  0.33 ng/ml
before STZ injection to 0.237  0.21 ng/ml after STZ
injection (Fig. 1C). Circulating glucagon concentrations
ranged from 134.78 pg/ml to 197.81 pg/ml before
administration of STZ (mean values 163.60  26.18 pg/
ml) and from 222.06 pg/ml to 363.23 pg/ml after STZ
administration (Mean values 294.08  66.5 pg/ml)
(Fig. 1D). Pre-STZ leptin mean values were
7.44  3.9 pg/ml. Post-STZ leptin mean values were
4.9  2.4 pg/ml (Fig. 1E). Mean NEFA levels increased
from 0.45  0.16 mEq/l before STZ injection to
0.94  0.5 mEq/l after STZ injection (Fig. 1F). These
data show that diabetes was clearly induced in otherwise
normal baboons using pharmaceutical-grade STZ. All
animals (N = 4) developed fasting post-STZ frank
hyperglycemia associated with fasting levels of low
plasma insulin, C-peptide, and leptin concentrations,
and high plasma glucagon and NEFA.
Circulating levels of glucose, insulin, C-peptide, and
glucagon during the intravenous glucose tolerance test
before and after STZ administration
Glucose
IVGTTs (60 minutes) were performed in all our
research animals before and after STZ administration.
Baseline pre-STZ blood glucose concentrations peaked
within the first two to six minutes to mean values of
415.2  84.6 mg/dl immediately after a 50% dextrose
(0.5 mg/kg) IV bolus. Mean glucose values at 8–15 min-
utes were 283.6  35.3 mg/dl. Mean glucose values at
30–45 minutes were 120.2  47.7 mg/dl. Mean glucose
levels returned to normal by 60 minutes (64.5  23.1
mg/dl). In contrast, IVGTTs performed after STZ
administration showed post-STZ blood glucose concen-
trations peaked within the first 2–6 minutes to mean val-
ues of 504.55  127.33 mg/dl. Mean glucose values at
8–15 minutes were 372.6  67.1 mg/dl. Mean glucose
values at 30–45 minutes were 297.3  48.4 mg/dl.
Mean blood glucose values remained frankly elevated
(A) (B)
(C) (D)
Fig. 2 Mean circulating levels of glucose (A, B, C), insulin (A, D), C-peptide (B), and glucagon (C, D) measured during the intravenous glucose
tolerance test (IVGTT) curves before (solid lines) and after (dashed lines) pharmaceutical-grade STZ administration.
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(282  47.8 mg/dl) above values observed at 60 min-
utes before STZ administration (Fig. 2A–C).
Insulin
Pre-STZ mean insulin levels during the first 2–6 minutes
were 102.8  53.4 lU/ml. Mean insulin values at 8–15
minutes were 88.7  38.8 lU/ml. Mean insulin values at
30–45 minutes were 70.5  47.3 lU/ml. Mean insulin
levels were 24.2  19.8 lU/ml by 60 minutes. In con-
trast, post-STZ mean insulin levels were steadily low dur-
ing the 60 minutes. IVGTT (3.0  1.9 lU/ml) (Fig. 2A).
C-peptide
Pre-STZ mean C-peptide levels during the first 2–6 min-
utes were 3.21  1.7 ng/ml. Mean C-peptide values at
8–15 minutes were 2.9  1.6 ng/ml. Mean C-peptide
values at 30–45 minutes were 2.6  1.7 ng/ml. Mean C-
peptide levels were 1.14  0.6 ng/ml by 60 minutes. In
contrast, post-STZ mean C-peptide levels were steadily
low during the 60 minutes. IVGTT (0.26  0.2 ng/ml)
(Fig. 2B).
Glucagon
Compared to mean fasting values, IVGTT pre-STZ
mean glucagon levels during the first 2–6 minutes
decreased to 147.4  56.9 pg/ml. Mean glucagon values
at 8–15 minutes also decreased to 99.6  20.2 pg/ml
and continued to be decreased at 30–45 minutes.
(124.4  50.8 pg/ml). Mean glucagon levels were
184.09  81.9 pg/ml by 60 minutes. In contrast, IV-
GTTs performed after STZ administration showed
increased blood glucagon concentrations within the first
2–6 minutes (mean values of 215.77  88.5 pg/ml). The
glucagon levels remained steadily elevated at 8–15 min-
utes (mean values of 209.06  84.1 pg/ml) and at 30–
45 minutes (mean values of 214.50  94.3 pg/ml).
Mean glucagon levels were 219.18  85.4 pg/ml by
60 minutes post-STZ (Fig. 2C and D).
Triphasic blood glucose response
The advantage of the tether system and indwelling sur-
gical catheter implants in all our treated baboons
enabled us to plan an accurate strategy to frequently
draw blood samples to carefully monitor the metabolic
environment before and after pharmaceutical-grade
STZ administration. All baboons participating in our
research protocol that were treated with pharmaceuti-
cal-grade STZ (Zanosar) developed a triphasic blood
glucose response to STZ administration (Fig. 3).
Fig. 3 Representative mean values of the triphasic blood glucose response from all baboons treated with pharmaceutical-grade STZ (Zanosar)
(black solid line). Dextrose was administered continuously. The mean glucose infusion rate (GIR) is indicated in mg/kg/minute (red dotted line).
Intermittent 50% dextrose bolus, if clinically needed (1 ml/kg IV), was administered. Continuous IV insulin administration was started 38–
40 hours after IV STZ injection.
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During the initial phase, there was a marked glucose
increase reaching a mean of 280 mg/dl approximately
6–8 hours after STZ IV administration. This peak was
followed by a steady glucose decrease to a mean of
100 mg/dl between 16 and 18 hours after STZ IV
injection. This drop was accompanied by a second and
sustained mean glucose increase of 325 mg/dl approxi-
mately 38–40 hours after STZ IV administration,
establishing a diagnosis of a frank hyperglycemic state.
Continuous dextrose administration started with a
mean rate of infusion of 1 mg/kg/minute. The rate
increased by the end of phase one (7.5 hours after
STZ IV injection) to 3 mg/kg/minute. The infusion
rate was steadily increased from 5–8.5 mg/kg/minute
between 12 and 23 hours after STZ injection to main-
tain glucose levels above 75 mg/dl. Intermittent 50%
dextrose boluses, if clinically needed (1 ml/kg IV),
were administered between 14 and 18 hours to avoid
hypoglycemia. As the glucose levels increased as
expected during phase three (20–40 hours after STZ
injection), the clinical need to infuse dextrose became
unnecessary. A continuous IV insulin infusion (0.1–
0.5 U/kg/hour) was then indicated after 38–40 hours
of IV STZ administration (Fig. 3). A triphasic blood
glucose response of individual baboons during and
after successful induction of hyperglycemia after the
administration of STZ was observed in each case
(Fig. 4).
Morphology of pancreatic islets using triple
immunofluorescent staining
Panels A and B of Fig. 5 show staining with anti-insulin
(red), antiglucagon (green), and DAPI (blue) for the cell
nucleus. Panels C and D show triple staining for insulin
(red), C-peptide (green), and DAPI (blue). One other-
wise healthy baboon (ID No. 11692) scheduled for
euthanasia that matched the age and weight criteria for
the study population (N = 4) was opportunistically
identified to harvest pancreatic tissue at the time of nec-
ropsy and be considered as the normal control for pan-
creatic staining. In this normal baboon, the b-cells
dominate islet structure (Fig. 5A). Interestingly, after
administering pharmaceutical-grade STZ to baboon ID
No. 18175, all b-cells were initially destroyed, but islet-
like structures containing large clusters of alpha cells are
abundantly seen (Fig. 5B). The confocal images of triple
staining for insulin and C-peptide show normal b-cell
islet architecture for baboon No. 11692 with the pres-
ence of insulin staining (Fig. 5C). In contrast, absence
of insulin and C-peptide staining is seen for baboon No.
18175 after STZ administration (5D).
Adverse effects after STZ administration
Kidney and liver toxicity are complications in STZ-
injected animals. As shown in Tables 1 and 2, these
Fig. 4 Individual triphasic blood glucose response observed in every baboon post-STZ IV administration.
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complications were absent (non-significant) in our trea-
ted baboons.
Discussion
In this study, our results show that we were able to suc-
cessfully induce frank hyperglycemia in four conscious
tethered baboons with minimal morbidity by IV admin-
istering a single dose of pharmaceutical-grade STZ
(Zanosar). Mean values of biochemistry tests and labo-
ratory results in individual STZ-injected animals after
STZ administration showed minimal (non-significant)
changes in kidney (creatinine, BUN), liver profiles
(ALT, AST), and electrolytes (Tables 1 and 2). We need
to begin by clarifying that this was a short-term study in
which the safety and efficacy effects of the alkylating
cytotoxic agent STZ were analyzed 1 week after this
drug was administered to our study animals. Our four
baboons were part of a research project proposing a
novel approach in which non-viral gene therapy was
delivered to pancreatic islets using ultrasound-targeted
microbubble destruction (UTMD) [43]. Our results from
the gene therapy protocol have already been published
[11]. Here, we will discuss the methods and results and
analyze the strengths and limitations of this study in
utilizing a tether system and indwelling catheter
implants to induce a diabetic phenotype after STZ
administration.
All animals were carefully chosen based on mainte-
nance of food intake, general attitude toward study
technical staff (submissive, aggressive, etc.), general
attitude toward study veterinarian, and comfort level
with presence of technical staff in bay. Response to
sham-tethering (attitude, time at the front of cage,
etc.), tether jacket fit, and normal feeding habits were
carefully monitored and documented. Our protocol
followed expert behavioral training techniques already
established [23].
A major advantage of the tether and indwelling cathe-
ter system is that the presence of IV catheter implants
allows for a continuous flow of fluids. IV hydration is a
key factor in preventing not only the most common and
devastating adverse events secondary to the alkylating
cytotoxicity of STZ to liver and kidney, but, most
importantly, in preventing dangerous hypoglycemia due
to very large amounts of insulin released from the
destruction of b-cells during STZ administration [58].
(A) (B)
(C) (D)
Fig. 5 Microscopic and confocal images.
(A, B) triple staining for insulin (red), gluca-
gon (green), and DAPI (blue); (C, D) triple
staining for insulin(red), C-peptide(green),
and DAPI (blue). (A, C) baboon ID no. 11692:
Normal pancreas from healthy na€ıve baboon;
(B, D) baboon ID no. 18175 post-STZ treat-
ment; Scale bar at (A) and (B) is 200 lm,
Scale bar at (C) and (D) is 100 lm.
Table 1 Mean values of laboratory tests after STZ administration.
Phenotypes
Mean + SD
P-valuePre-STZ Post-STZ
WBC (thous/mm3) 7.77  2.41 11.54  3.48 0.114
Hematocrit (%) 40.56  3.41 44.56  17.14 0.611
Creatinine (mg/dl) 1.16  0.13 1.62  0.81 0.259
BUN (mg/Ddl) 9.79  2.25 11.80  4.14 0.434
ATL/SGPT (U/l) 36.12  4.88 60.00  24.44 0.116
AST/SGOT (U/l) 32.56  4.50 43.40  23.19 0.408
ALK PHOS (U/l) 128.97  30.64 265.40  180.27 0.159
Carbon dioxide
(mEq/l)
31.08  1.76 26.70  7.08 0.247
Anion Gap (mEq/l) 10.19  2.54 10.08  1.09 0.940
P < 0.05, n = 4 baboons.
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IV hydration protocols to prevent the toxic profile of
IV STZ administration in NHP have been poorly
reported in the literature. One comprehensive paper
reported that 10 cynomolgus monkeys with permanent,
surgically implanted, indwelling IV lines were prehy-
drated with 10 ml/kg/hour of 0.9% NaCl IV for 8–
10 hours before STZ administration, increasing the rate
of fluid infusion to 15 ml/kg/hour for two more hours
after STZ injection as a preventive measure to reduce
kidney toxicity. This study claimed to be the first to use
pharmaceutical-grade STZ (Zanosar) 150 mg/kg due to
perhaps greater purity and less variability than tradi-
tional-grade STZ routinely used to induce b-cell destruc-
tion. The authors concluded that compared to
traditional-grade IV STZ administration, their com-
bined IV fluid therapy and pharmaceutical-grade STZ
(Zanosar) were key factors in achieving diabetes induc-
tion safely and without adverse effects. They did not
report any symptoms of severe life-threatening adverse
events such as pulmonary edema, rapid onset of
advanced nephrotoxicity, or metabolic acidosis. They
also reported a triphasic blood glucose response, detect-
ing significantly low blood glucose levels during the sec-
ond phase of the triphasic response, corresponding to a
massive insulin release from dying b-cells [52, 58].
Our comprehensive therapeutic strategy included an
intensive IV hydration protocol 24 hours before and
48 hours after STZ injection. STZ is a chemotherapeu-
tic cytotoxic drug associated with devastating side
effects, namely liver toxicity, pulmonary edema, organ
failure and, most prominently, nephrotoxicity and life-
threatening metabolic ketoacidosis [54]. It has been
documented that the kidney is the first target post-
STZ administration [53]. STZ is rapidly cleared by the
kidneys within 48 hours after an acute administration.
The drug is primarily excreted in urine [35]; therefore,
using intensive IV fluid therapy to induce high urinary
flow rates protects the kidney from injury during treat-
ment with this chemotherapeutic agent [49]. Our inten-
sive IV hydration therapy is based on recommended
protocols used in humans with the objective of pre-
venting renal toxicity induced by IV STZ injection.
Current hydration protocols recommend 2.5–3.5 l of
fluid per meter2 per 24 hours, beginning 12 hours
before the administration of chemotherapeutic agents
associated with kidney toxicity and continuing for 24–
48 hours. The main goal is to measure fluid intake vs.
output to avoid a fluid negative balance and prevent
loss of renal function by judicious intensive IV hydra-
tion therapy [69].
Recent recommendations [22, 23] to avoid adverse
events associated with the use of chemotherapeutic STZ
to induce diabetes in NHP have been published. The
authors based their recommendations on long-term
experience with a cohort of 78 cynomolgus and rhesus
macaques. They established elegant up-to-date, state-of-
the-art, pre-treatment regimens, laboratory evaluations
post-STZ administration, flow charts to assess triggering
factors for STZ adverse events, and validated critical
clinical tools to detect, prevent and manage the most
serious side effects after STZ administration. Their pro-
tocol was not based on the presence of permanent surgi-
cal indwelling catheter implants and preventive intensive
IV hydration. Instead, their methodology was based on
training NHP to cooperate with hand feeding and
drinking, shifting and limb presentation. They reported
that 8% of STZ-treated animals from that cohort mani-
fested severe life-threatening adverse effects [22]. The
outstanding measures they established did not fully
eliminate the expected major life-threatening com-
plications of kidney toxicity and metabolic acidosis.
Therefore, the choice of utilizing permanent surgical
Table 2 Laboratory results in individual STZ-injected animals
Normal values
Kidney tests Electrolytes
Creatinine
(mg/dl)
BUN
(mg/dl)
Sodium
(mEq/l)
Potassium
(mEq/l)
Chloride
(mEq/l)
Carbon dioxide
(mEq/l) Anion Gap
0.8–1.5 8–22 135–148 3.0–4.1 98–111 24–34 7.5–16.8
Pre-STZ
26457 1.1 11 143 4.1 102 33 11.6
20105 1.4 8 142 3.7 106 31 8.9
26104 1.2 12 143 4.0 105 32 10.1
18175 1.1 11 146 4.0 107 32 11.0
Post-STZ
26457 2.8 17 143 3.7 116 19 11.5
20105 2.0 21 146 3.3 122 17 10.3
26104 1.3 12 140 3.6 103 29 11.6
18175 1.1 10 141 3.7 106 29 9.4
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indwelling catheter implants and an aggressive preven-
tive and immediate post-STZ IV hydration protocol like
the one presented in this paper should strongly be con-
sidered when administering IV STZ to NHP, given the
recommended preventive intensive IV fluid therapy
protocols in humans before the administration of che-
motherapeutic agents associated with kidney toxicity
[49, 69].
The surgical tether catheter implants offer the crucial
advantage of a continuous measurement of circulating
blood glucose levels before and after IV STZ injection.
We were able to fully characterize the triphasic response
in blood glucose after STZ administration. Such tripha-
sic response post-STZ injection [33] has been described
in NHP and mice [59, 68]. As shown in Fig. 3, during
phase one (7–8 hours after IV STZ administration)
blood glucose rises. Pancreatic b-cell damage is initiated
by STZ, leading to transient hyperglycemia due to acute
inflammation, inability of the b-cells to oxidize glucose
and sudden and continuous breakdown of liver and
muscle glycogen. Phase two (between 9 and 20 hours
post-STZ IV injection) is a critical physiological stage
with adverse effects which may be severe enough to lead
to death. There is further destruction and disruption of
b-cells by STZ resulting in a massive release of insulin,
pronounced muscle insulin-mediated glucose uptake,
and a steady fall in circulating blood glucose levels, lead-
ing to dangerous hypoglycemia. Subsequently, phase
three is observed in our protocol between 20 and
40 hours and onwards after STZ injection, and is char-
acterized by the permanent rise in glucose levels, a per-
sistent and irreversible hyperglycemic state and a total
degranulation with structural alterations in pancreatic
b-cells [25, 40].
The dangerous hypoglycemic phase after IV STZ
administration has been discussed in depth only rarely
in peer-reviewed papers reporting induction of diabetes
in NHP with this chemotherapeutic drug [22, 23, 38, 39,
52]. It has been documented that metabolic acidosis
occurred mainly during the second phase when blood
glucose fell to low levels after IV STZ injection [52]. In
the past, high-dose STZ administered to adult rhesus
macaques has resulted in ‘unacceptable mortality rates
attributed to anuria and hypoglycemic crisis’ [60].
Hypoglycemia is defined as blood glucose <70 mg/dl
[16, 57], whereas severe hypoglycemia is defined as
blood glucose <40 mg/dl [56]. During hypoglycemia,
lack of glucose supply to neurons can lead to confusion,
brain damage [1], seizures, and death [2, 64]. Six to ten
percent of deaths in young people with T1DM are
directly attributable to hypoglycemia [18]. It has been
hypothesized that abrupt cardiac arrhythmias con-
tribute to severe hypoglycemia–induced sudden death.
Sudden deaths caused by insulin-induced severe hypo-
glycemia are mediated by lethal cardiac arrhythmias
triggered by brain neuroglycopenia and a marked sym-
pathoadrenal response [50]. Moreover, glucose counter
regulation is a function of prior hypoglycemic episodes
which sets up a vicious cycle of one hypoglycemic epi-
sode increasing the likelihood of subsequent hypoglyce-
mia and progressive decay in the counterregulatory
response. In a normal physiological environment, hypo-
glycemia immediately elicits a counter regulatory
response [44]. However, recurrent hypoglycemia blunts
the activities of counter regulatory responses. It has
been described that healthy individuals who have two
hypoglycemic episodes in a day show inhibited glucose
counter regulatory response. The defective counter regu-
latory response is also affected by the reduced auto-
nomic response which further decreases hepatic glucose
production [28].
On our protocol, baboon ID No. 18175 experienced
an unexpected case of severe hypoglycemia during the
second phase after IV STZ administration lasting
9 hours (between 10- and 19-hour post-STZ injection)
(Fig. 4, red solid line). The presence of the permanent
indwelling IV catheter implants and the tether system
allowed us to measure moment-by-moment circulating
arterial glucose levels and permitted us to administer
intermittent 50% dextrose bolus (1 ml/kg IV) if clini-
cally needed, while continuously infusing dextrose 10–
30% to keep the glucose levels within normal limits.
It is clear that dangerous hypoglycemia is the hall-
mark of the second phase after STZ injection. This is
probably because b-cell destruction is so rapid that insu-
lin in the destroyed b-cells may enter the blood stream
within a short period of time. A similar phenomenon is
frequently observed just before the onset of fulminant
T1DM [32]. In this deadly pathology, pancreatic b-cells
are completely destroyed in the same way as is evident
in rodents and NHP when IV STZ is injected into their
bloodstreams to provide models of T1DM [65]. In ful-
minant, T1DM the process of b-cell destruction and
progression of hyperglycemia and ketoacidosis are
extremely rapid. The duration of the disease from a nor-
mal b-cell mass and normoglycemia to almost total
destruction of b-cells and ketoacidosis rarely exceeds
1 week. Without appropriate therapy, the death of the
patient is inevitable [31]. It was previously reported that
the rapid onset of b-cell destruction and ensuing diabe-
tes induced by IV STZ injection mimics that of fulmin-
ant T1DM [30].
The results of our study clearly document an acute
onset of diabetes and b-cell destruction with similar
clinical and pathological findings to fulminant T1DM.
Our advantage is that we know STZ administration will
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cause the pathological scenario. In fulminant T1DM,
the etiopathogenic factors causing the deadly disease are
unknown. Therefore, if we already know what to expect
after STZ IV administration, all preventive and inten-
sive clinical procedures recommended in this study
should be implemented.
Recent evidence has shown that glucagon, under the
control of insulin at paracrine levels, is a key regulator
of glucose metabolism and that hyperglucagonemia
(glucagon excess) and unregulated alpha cell dysfunc-
tion in T1DM, rather than insulin deficiency, are pro-
foundly involved in the pathophysiology of T1DM. In
normal physiologic conditions, glucose-responsive b-
cells normally regulate juxtaposed alpha cells. In the
T1DM state, without intra-islet insulin, unregulated
alpha cells hypersecrete glucagon, which directly causes
hyperglycemia [24]. A series of studies in rodent models
of T1DM have confirmed that increased plasma gluca-
gon concentration is also an important mediator of met-
abolic dysregulation. Glucagon stimulates hepatic
glucose production by activating the enzymatic path-
ways involved in both glycogenolysis and gluconeogene-
sis. In these rodents, b-cell destruction by STZ
administration leads to hypoinsulinemia and hyper-
glycemia as expected. Interestingly, plasma leptin
concentrations are decreased and plasma glucagon con-
centrations are increased in these animals. The com-
bined effects of hypoinsulinemia, hypoleptinemia, and
hyperglucagonemia lead to increased release of NEFA
from adipose tissue [46] (Fig. 6).
A significant finding in all tethered baboons treated
with IV STZ was that they developed hyperglucagon-
emia. In Fig. 2D, the black solid line shows an IVGTT
curve with expected mean glucagon levels returning to
normal after a 60-minute glucose challenge, also show-
ing a mean highly abnormal glucagon curve after Zano-
sar STZ (black dashed line). These findings are
consistent with recently published data indicating that
the absence of leptin and hyperglucagonemia contrib-
utes to the development of T1DM [46]. We found the
same biochemistry pattern in our baboons treated with
IV STZ. They developed frank hyperglycemia associ-
ated with low levels of plasma insulin, C-peptide and
leptin concentrations, and high plasma glucagon and
NEFA concentrations (Fig. 1A–F). Triple immunofluo-
rescent staining of pancreatic tissue analyzed before and
after STZ injection corroborated these findings (Fig. 5).
To our knowledge, the present study is the first to per-
form a comprehensive analysis of the key hormones and
metabolites influencing the physiologic control of the
insulin–glucose axis and the alpha and beta cell biology
by dynamically measuring fasting glucose, insulin,
C-peptide, glucagon, leptin, and NEFA circulating
levels pre- and post-STZ administration in conscious
tethered baboons.
Our results and findings from recently published,
new, cutting-edge research indicating that the absence of
leptin and hyperglucagonemia triggers T1DM [46] may
have some implications for the diagnostic criteria of the
induction of the diabetic phenotype [14] after STZ
administration. It seems that the insulino-glucocentric
diagnostic view exclusively centered on measurements of
glucose, insulin, and C-peptide should be reviewed to
consider the diagnosis of the STZ-induced diabetic
phenotype with a broader view including a leptino-
glucagonocentric makeover according to the new patho-
physiology of T1DM [46, 61].
In summary, our comprehensive therapeutic strategy
(tether system and permanent indwelling catheter
implants during the length of the study, aggressive
hydration protocol, management for discomfort and
Fig. 6 b-Cell destruction secondary to IV STZ administration to con-
scious tethered baboons causes C-peptide to fall below detection
levels, hypoinsulinemia, and frank hyperglycemia both fasting and
after an IVGTT. Islet alpha cell proliferation (Fig. 5) and insulin defi-
ciency increases plasma glucagon concentration. Hypoinsulinemia
decreases the secretion of leptin from adipose tissue. Hypergluca-
gonemia is the result of hypoinsulinemia and hypoleptinemia second-
ary to insufficient insulin- and leptin-mediated suppression of alpha
cell glucagon expression. Hypoleptinemia also increases the HPA
axis activity and increased cortisol secretion from the adrenal glands,
which in turn increases the release of NEFA from adipose tissue. Ele-
vated levels of circulating NEFA are delivered to the liver and become
ketogenic substrates leading to excessive release of glucose and ke-
tone bodies into the bloodstream, contributing to hyperglycemia and
ketoacidosis.
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anxiety, analgesia for pain relief, moment-by-moment
monitoring of glucose levels post-STZ administration,
continuous intravenous insulin therapy, total parenteral
nutrition if needed, and early detection of adverse effects
with a comprehensive laboratory workup to measure
blood chemistries and metabolic factors) was successful
to completely induce diabetes with IV pharmaceutical-
grade STZ safely and without adverse events in con-
scious tethered baboons. We were able to characterize a
triphasic blood glucose response after IV STZ injection
indicating a complete and successful induction of the
diabetic phenotype.
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